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ABSTRACT 
Phenomenological screening of small molecule libraries for anticancer activity yields 
potentially interesting candidate molecules, with a bottleneck in the determination of 
drug targets and the mechanism of anticancer action. A novel approach to drug target 
deconvolution compares the abundance profiles of proteins expressed in a panel of 
cells treated with different drugs, and identifies proteins with cell-type independent 
and drug-specific regulation that is exceptionally strong in relation to the other 
proteins. Mapping top candidates on known protein networks reveals the mechanism 
of drug action, while abundant proteins provide a signature of cellular death/survival 
pathways. The above approach can significantly shorten drug target identification, 
and thus facilitate the emergence of novel anticancer treatments. 
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Target-directed discovery is the way pharmaceutical industry most often uses in 
searching for new drugs, with compound libraries screened for binding or activity 
against a known protein target. In contrast, phenomenological screening of small 
molecule libraries is a “black-box” target-agnostic approach, where compounds are 
interrogated in cell-based assays with a readout linked to a disease-relevant process 
(e.g. cancer cell apoptosis). Arguably, this latter approach to drug discovery offers 
better chances for success because more targets are addressed and the assay is more 
relevant to human physiology. Indeed, between 1999 and 2008, of the first-in-class 
compounds that were approved by the FDA, only 38% had been derived from target-
based screening, while the rest - from phenotypic screening.1 However efficient, 
phenomenological screening has a serious bottleneck in drug target discovery and 
validation. Less than 200 small-molecule anticancer drugs approved by FDA have a 
known mechanism of action, while thousands of promising molecules remain with 
poorly known or unknown targets.2,3 This mismatch between the number of promising 
compounds and the knowledge of the targets and underlying mechanisms of action 
represents one of the greatest unmet needs in war against cancer.  
Mass-spectrometry based proteomics is a well established tool in drug 
discovery.4 Unlike transcriptomics that covers the whole range of expressed genes, a 
typical untargeted 1D LC-MS/MS proteomics experiment can detect and quantify up 
to 5,000 proteins, which is less than half of the expressed human proteome.5 
However, proteomics technology rapidly progresses, and deep proteome analysis with 
more than 8,000 protein groups quantified is becoming increasingly available.6–9 
Besides, measuring relative protein concentrations accounts not only for protein 
expression but also for protein degradation, which makes proteomics particularly 
valuable in drug target discovery. Indeed, drug attachment often stabilizes the protein 
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and makes it more resistant to degradation, which leads to protein target 
accummulation.10,11 Alternatively, drug-induced protein translocation from nucleus to 
cytoplasm can cause its rapid degradation.12  
Recently, significant hope has been associated with dynamic proteomics, 
which had a promising start in drug target discovery. In a landmark experiment 
(performed without the use of mass spectrometry), the known target for camptothecin, 
DNA topoisomerase 1 (TOP1), has been found among the proteins with fast and deep 
abundance reduction upon drug application.12 However, detailed analysis of the 
dynamic proteomics data using time-dependent abundance changes as sole criteria 
could only identify TOP1 as the 35th most likely candidate among ca. 900 quantified 
proteins.13  
This result epitomizes the main weakness of the dynamic proteomics approach 
to drug target discovery: while a multitude of proteins change their abundance upon 
drug application (in the cited experiment, all measured protein abundances have 
changed within 48 h),12 many changes have low specificity in respect to the drug. 
Therefore, appropriate filtering (“in silico target purification”) is needed to disregard 
these unspecific proteins and identify the true drug target. Pathway analysis can 
provide such a filter; being applied to the dynamic proteomics dataset, it identified 
TOP1 together with only eight other likely candidates.13 However, while of clearly 
significant potential for drug discovery, the pathway analysis approach has a number 
of shortcomings limiting its generality. Importantly, it searches targets among the 
known key nodes (bottleneck regulatory molecules) in the pathway database, relying 
on already known information for data filtering. In essence, only known potential 
drug targets will be discovered, with the discovery process being database-sensitive. 
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An alternative approach could be to focus on early times after drug 
applications. The rational is that the initial cellular response should be most drug-
specific, while the late response (e.g., apoptosis) is largely generic. However, in an 
analysis14 of early response times of RKO cells to a broadly used anticancer 
substance, 5-fluorouracil (5-FU), which has a well-known target, thymidylate 
synthase (TYMS), the changes in the first few hours past drug treatment have been 
too small to be measured with sufficient statistical confidence.  
Recently, we have found that the apoptotic response is much less generic than 
has previously been thought, and that in fact proteome changes become more apparent 
and drug-specific in late apoptosis. Based on this finding, we have developed a new 
method of drug target identification that does not require a priori knowledge of 
signaling or metabolic pathways and has a high robustness. The method achieves in 
silico target purification using an expression proteomics dataset obtained from a 
treatment of a panel of cell lines (2 cell lines) with a panel of drugs (3 molecules). 
The approach is based on the assumptions that the drug target significantly changes its 
abundance (up or down) in late apoptosis, and that the drug target abundance behaves 
similarly for different cell lines that are sensitive to the drug. It is understood that the 
validity of these assumptions will be a factor limiting the applicability of the 
approach; however, most systems tested so far complied with these assumptions. The 
method also capitalizes on recent developments in label-free proteomics5,15,16 that 
made possible analysis of 5000 proteins in a reasonably short time (3-4 h). This 
“high content proteomics”5 enabled in turn quantitative cross-comparison of several 
cell lines treated with multiple drugs, with several different times of treatments, all 
with adequate controls and replicate analyses. Below we describe a set of proof-of-
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principle experiments, where known protein targets for five drugs were correctly 
identified, often as top candidates, with novel plausible target candidates revealed.  
RESULTS 
Experiment I. Three cell lines (melanoma A375, lung cancer H1299 and colon cancer 
HCT116) were treated with 5-FU, methotrexate (MTX), paclitaxel (PCTL), 
doxorubicin (DOXO) and tomudex (TDX). In total, 5037 proteins were identified 
with FDR<1%. Label-free quantification across all samples was performed for 4168 
proteins that were identified with at least two unique peptides. 
The method’s workflow is depicted in Figure 1. After LC-MS/MS based 
proteomics analysis of the panel of cell lines treated by a panel of drugs and controls, 
regulation Reg and specificity Spec were calculated for each protein, cell line and 
treatment. Regulation and specificity values were then subjected to rank product 
analysis that calculated the final ranks and p-values (using the Bonferroni correction), 
thus identifying significantly regulated proteins. The protein list was then sorted by p-
values in ascending order. The few top proteins with statistically significant p-values 
represented the most likely drug targets, while all statistically significant proteins 
were mapped on protein-protein interaction networks to identify the mechanism of 
drug action. Finally, the most abundant part of the proteomes was mapped on a 2D (or 
higher dimensionality) plot using principal component analysis to reveal the pathways 
of cellular death and survival. Below we discuss in detail the implementation of the 
method for each of the three levels of description (drug target, mechanism of action 
and death/survival mode).  
Drug target. Figure 2a) illustrates the in silico drug target purification 
procedure by showing the regulation of TUBB2A (ß-tubulin) in different cell lines 
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and under different treatments. For all three cell lines, this protein demonstrates a 
consistent upregulation in PCTL treatment, which significantly exceeds the regulation 
levels in any other treatment or control. While the rank of TUBB2A for regulation 
and specificity is not higher than 7 among 4168 proteins for any cell line, the 
combined rank is 1, correctly identifying TUBB2A as the drug target for PCTL. Two 
other tubulins are the next two most likely candidates. Altogether, 21 proteins are 
found statistically significant (at p<0.01) drug target candidates, of which five tubulin 
proteins (Supplementary Table 1). Similarly, 5FU dataset gave 15 significant protein 
candidates, with the known target TYMS being on the 4th position. In MTX treatment, 
the target DHFR ranks 1st among seven significant proteins. The TDX dataset features 
10 significant proteins, with the main target TYMS on the 1st position and the 
secondary target DHFR on the 3d position.  DOXO treatment yielded the smallest 
number of significant proteins (four), which was caused by high cell-type specificity 
of the drug’s action (DOXO primarily acts through DNA intercalation). Intermediate 
results illustrating the action of “in silico purification” for 5FU, TDX, MTX and 
PCTL are given in Table 1. 
Action mechanism. Analysis of the interaction networks encompassing 
protein candidates significantly regulated at p0.05 (32 proteins for 5FU, 9 for 
DOXO, 13 for MTX, 34 for PCTL and 20 for TDX) highlighted the drug action 
mechanism. For 5-FU, the main cluster involves ribosome (Figure 2c), the proteins of 
which were found specifically downregulated. This observation is in line with the 
previous finding that ribosome suppression is a significant element of 5-FU 
action.14,17 Networks for other drugs are shown in Supplementary Figure 1. As would 
be expected for non-random clusters, a great majority of proteins in clusters with 3 
molecules have same-sign regulation (up or down). For the largest clusters, the same 
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regulation have 13 out of 15 proteins (5-FU, down); 9 out of 11 (PCTL, up), and 9 out 
of 10 proteins (TDX, up). According to gene set enrichment analysis, cytosolic large 
ribosomal subunit (GO cellular component) proteins are overrepresented in 5-FU 
network (p=1.8E-4); protein polymerization (GO biological process; p=4E-4) in 
PCTL; and pyrimidine metabolism (KEGG; p=6E-5) in TDX. Thus, drug action 
mechanisms become apparent from such analysis.  
Death/survival mechanism. Two-dimensional principal component analysis 
of 100 most abundant proteins (average of the abundances in three cells lines), with 
data grouped according to treatments, revealed the evolution of the cellular 
proteomes, and thus highlighted the death/survival pathways. Figure 1g) demonstrates 
that the death/survival pathways in MTX and TDX treatments partially overlap, while 
those in 5-FU treatment are different from these two drugs, despite the fact that both 
5-FU and TDX target TYMS. 
Novel targets. The top protein candidates are likely to be strongly implicated 
in the mechanism of drug action, and may even represent novel targets for the applied 
drugs. For instance, overexpression of stratifin (isoform 1 of 14-3-3σ protein), which 
is found upregulated with a rank 2 in 5-FU treatment, has been suggested to predict 
resistance to 5-FU therapy in colorectal carcinoma patients.18 ASNS (glutamine-
hydrolyzing asparagine synthetase isoform b) is found downregulated on the 4th 
position in MTX treatment, which is consistent with this enzyme’s action being 
opposite to that of MTX.19 
Since starvation/senescence was included in the experiment, the proteomics 
dataset of this “natural environment” cell suppression could be processed in the same 
way as other datasets for drug-treated proteomes. In total, 91 proteins were found with 
p<0.01, much more than in any other treatment, which is consistent with many 
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molecules being targeted by the toxic waste products accumulated in the media.  
Among the top proteins, there are many known and prospective targets for anticancer 
therapy. For instance, thioredoxin (rank 3; downregulated) has been identified as a 
molecule of significant interest to chemotherapy20, while 3-hydroxyisobutyryl-CoA 
hydrolase (HIBCH) (upregulated; rank 6) is one of the targets for Quercetin, a 
molecule found in grape juice, which is being tested as a treatment of prostate cancer 
by diet (http://clinicaltrials.gov/ct2/show/NCT01912820). The most striking 
upregulation (Figure 2c) is shown by inter alpha-trypsin inhibitor heavy chain 2 
(ITIH2, rank 1). ITIH2 has earlier been suggested to act as a tumor-suppressing 
protein.21 We hypothesize that ITIH2 plays an important role in cancer cell survival at 
adverse conditions and thus represents a potential drug target.  
Experiment II. In a scaled-down experiment performed for the sake of 
verification, RKO (colon cancer) and A375 (melanoma) cells were treated with 
DOXO, 5-FU, camptothecin (CAMP) and PCTL. After data processing, in the 5-FU 
dataset, seven proteins were found with p<0.01, of which TYMS was on the 4th 
position (p=7.7⋅10-4). In the CAMP treatment, out of nine significant proteins, TOP1 
(target for CAMP) was on the 9th position with p=1.1⋅10-3. For PCTL, the target ß-
tubulin (TUBB8) was on the 7th position (p=1.3⋅10-3) out of 11 significant proteins 
(Supplementary Table 2). Therefore, even in this limited experiment with only two 
cell lines, the drug targets were confined to a small number (on average, nine) protein 
candidates.  
Experiment III. To determine the minimal experiment that can provide 
meaningful data, we have treated HCT116 cells with 5-FU for 24 h in a triplicate and 
analyzed the extracted proteins against a triplicate control grown for the same time. 
The experiment was repeated twice, one time using label-free quantification (3,800 
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proteins quantified), and another time – with TMT-10 quantification (4,800 proteins).  
In the label-free dataset (median coefficient of variation of protein abundances among 
the biological replicates was CV § 9%), the target TYMS was on the 28th position in 
terms of absolute regulation, while in the TMT-10 dataset (CV § 5%) – on the 11th 
position. Out of the 11 common proteins found among the top 30 proteins in both 
datasets, TYMS was on the 8th position. Therefore, meaningful results (10 potential 
candidates) can be obtained even from a single biological comparison. The key is 
obtaining sufficient statistical power, for which a low CV and an adequate number of 
biological replicates are required.  
Drug target behavior is exceptional. In order to investigate the question 
whether drug targets behavior is normal in terms of protein regulation, we built and 
analyzed predictive models for protein expression levels. The models predicted the 
regulation of each protein in each treatment based on the regulations of “best friends” 
of this protein in the same treatment. For this purpose, for each protein and each 
treatment we identified five proteins whose regulation in all other treatments and 
controls correlated most with that of the protein of interest. Linear regression of the 
regulations of these five proteins in other treatments provided a model for predicting 
the regulation of the protein of interest in a given treatment. Figure 2e shows that, as a 
rule, these predictions strongly (3σ) underestimated the experimentally observed 
regulations for the treatments where the protein was the drug target. Therefore, the 
targets’ regulations were not only strong, but exceptionally strong when a drug 
targeting them was applied. 
This observation prompted us to use the measure of protein exceptional 
behavior as an independent criterion in in silico purification. To quantify this 
parameter, we measured how exclusion or inclusion of a specific drug treatment 
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affected the correlation of a particular protein expression profile with all other 
quantified proteins (Supplementary Figure 2). Addition of this criterion to the ranking 
provided by regulation further narrowed the list of protein target candidates 
(Supplementary Table 3). For instance, at p0.05 significance, only one protein 
(TYMS) was identified as a target candidate for 5-FU, as were five proteins for 
PCTL, including four beta-tubulins. For TDX, two significant proteins were found, 
including TYMS with rank 1, and for MTX – also two proteins, with DHFR on the 1st 
position. For senescence/starvation, the list of candidates has shortened from 91 to 
seven, with a known oncogene CCNDBP1 on the 1st position and ITIH2 – on the 2nd. 
Abundant protein behavior reflects that of drug-specific proteins. The 
death/survival pathways were determined by mapping the abundance changes in most 
abundant proteins using supervised principal component analysis (the OPLS-DA22 
method). In order to investigate how the changes in the “top proteome” reflected the 
behavior of drug-specific proteins, 100 proteins (set A) were selected from experiment 
I with the highest reference abundance15 (geometric mean of integrated ion current of 
all unique peptides for all cell types and treatments). In parallel, 100 most drug-
specific proteins (set S) were selected with the smallest product of p-values calculated 
for each protein in each drug treatment. The S-set encompassed all revealed primary 
as well as most secondary drug target candidates. The A-sets and S-sets did not 
overlap; moreover, on average the S-proteins were more than one order of magnitude 
less abundant than the A-proteins. Yet the corresponding OPLS-DA plots were 
surprisingly similar. For each of the four components that were fitted by the OPLS-
DA model, the correlation between the respective components of the A- and S- 
models were greater than 0.8 (R2 ranged from 0.70 to 0.87; Figure 3).  
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The first (most significant) component of the S-model separates DOXO and 
PCTL on one side from 5-FU, MTX and TDX on the other, with ATP synthase 
ATP5A1 as the most typical DOXO representative and RNA binding motif protein 
RBM28 as the 5-FU champion (Supplementary Figure 3 a-b). Among the 
DOXO/PCTL-specific proteins, there is also a group of tubulins.  TYMS is found 
among the eight most 5-FU/TDX/MTX-specific proteins. The second component 
(Supplementary Figure 3 c-d) separates 5-FU and TDX/MTX treatments. Here, up-
regulation of eukaryotic translation initiation factor EIF4B and eukaryotic translation 
elongation factor EEF1B2, as well as down-regulation of ribosomal protein RPL23A 
are most specific for 5-FU, while up-regulation of DHFR, TK1, CDK1 and PRIM1 
are specific for TDX/MTX. Interestingly, TYMS is found in the middle group in this 
component. The component 3 (Supplementary Figure 3 e-f) separates PCTL from 
DOXO. Up-regulated tubulins and down-regulated BPTF are specific for PCTL, 
while DOXO-related proteins are CDK2 and SEC14L2. The component 4 
(Supplementary Figure 3 a-f) differentiates TDX (the specific group of proteins 
includes CDK2, PRIM1, TK1 and TYMS) from MTX (SYNJ2, SEC14L2 and 
DHFR).  
Discussion  
Just a few years ago, cross-comparison of three cells lines at the baseline to the depth 
of 5,000 proteins has been reported for the first time.23 Rapid recent progress in 
proteomics instrumentation and software have led to a marked decrease in the 
duration of a typical proteomics experiment, enabling analysis of 5,000 proteins in 
the time frame of 2 h.16 This opened a previously unexplored opportunity to apply 
cellular proteomics to dozens,8 and in perspective – hundreds and thousands of 
proteomes,7 enabling cross-comparison between different cell lines grown at different 
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conditions. This development unlocked the analytical power of the proteome cross-
comparison, which created a basis for the current study. 
The panel of tested drugs encompasses such diverse mechanisms as DNA 
and/or RNA synthesis inhibitors (5-FU and TDX), antifolate agents (MTX), tubulin-
active antimitotic agents (PCTL), and TOP1 inhibitors (CAMP).3 The similarity in the 
formally assigned target or mechanism was not, however, a determinant for the 
similarity in the death/survival pathway. Indeed, MTX and TDX have formally 
different mechanisms of actions, but the proteomes of dying/surviving cells were 
rather similar, while being significantly different from the proteome of cells that 
underwent 5-FU treatment, which targets the same protein (TYMS) as TDX. 
The results of the current study are supportive of the hypothesis that the 
protein drug target exhibits exceptional regulation compared to other proteins that 
change their abundance in a way harmonic with the abundances of other co-regulated 
proteins. It is worth investigating how general this feature is, on a much larger panel 
of drugs, and with a broader panel of cell lines. The method, if proven general, can 
significantly shorten drug target identification, which is one of the major bottlenecks 
in the drug discovery procedure. Its findings need however be verified by orthogonal 
techniques, such as binding assays. Even with this limitation, high-content proteomics 
has a chance of becoming an important, perhaps even irreplaceable, tool in drug target 
discovery.  
Within the current experiments, it was not possible to differentiate between the 
death and survival pathways. A separate study will be needed, where the dying cells 
are analyzed separately from the surviving cells, preferably in dynamics. Nonetheless, 
the finding that the OPLS-DA analysis of 100 most abundant proteins mimicked that 
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of 100 most regulated, drug-specific proteins strongly suggests that the mechanisms 
of drug action and the death/survival pathways are intimately linked. The old 
paradigm that different triggers of cellular death lead to a generic apoptotic pathway 
is thus thoroughly rejected. In fact, the opposite seems to be true – each of the tested 
drug imprinted a unique signature that was easily discernable even on a limited set of 
household proteins. Thus, “shallow” proteomics analysis monitoring the phenotype 
evolution of the top cellular proteome and taking as little as 30 min could thus be used 
in large-scale screening of drug action mechanisms.   
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FIGURE LEGENDS 
Figure 1. General workflow of the proteomics based method of drug target 
identification.  
(a) a panel of cell lines is treated by a panel of drugs and controls, in biological 
triplicates; (b) LC-MS/MS based proteomics identifies and quantifies ca. 5,000 
proteins; (c) for each protein, cell line and treatment, regulation Reg and specificity 
Spec are calculated; (d) for each treatment, final protein ranks based on Reg and Spec 
and the p-values are calculated, protein list is sorted in ascending order of p-values; 
(e) top significant proteins represent the most likely drug targets; (f) top n statistically 
significant proteins are mapped on protein networks to identify the drug target 
mechanism; (g) most abundant part of the proteomes is mapped using principal 
component analysis to reveal the cell death/survival pathways. 
Figure 2. Protein drug targets behavior in the cancer cell lines under the treatment 
with selected drugs. 
Regulation of proteins upon different treatments for three cell lines: (a) TUBB2A, (b) 
DHFR and (c) ITIH2. (d) Mapping of significant proteins on known networks of 
protein-protein interactions reveals the mode of 5-FU action via ribosome suppression 
together with TYMS inhibition. (e) Distributions of prediction errors of protein 
regulations (regulation – prediction) reveal exceptional behavior of drug targets (3σ 
area is shaded). 
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Figure 3. OPLS-DA score plots for discriminative models based on two sets of 
proteins: top 100 most abundant proteins (set A) and top 100 most drug-specific 
proteins (set S). 
(a) OPLS-DA score plot (components 1-2) for set A; (b) OPLS-DA score plot 
(components 1-2) for set S; (c-f) corresponding scatter plots (components 1-4) 
comparing OPLS-DA scores of the A-set and S-set. 
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TABLES 
Table 1. Ranks for Specificity/Regulation for known protein targets (in parentheses) 
of four drugs in different cell lines.    
Cell line 
5-FU 
(TYMS) 
MTX 
(DHFR) 
PCTL 
(TUBB2A) 
TDX 
(TYMS) 
Melanoma 44/70 1/1 38/12 18/3 
Lung 11/7 2/2 7/12 65/11 
Colon 136/813 8/9 55/30 11/8 
Final 4 1 1 1 
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SUPPLEMENTARY MATERIALS 
Supplementary Table 1. Label-free proteomics quantification data and protein drug 
target identification results based on Regulation and Specificity for Experiment 1. 
Cell lines HCT116, A375, and H1299 were treated with 5-FU, TDX, MTX, PCTL 
and DOXO, as well as DMSO (control), or left in unchanged media for 
senescence/starvation (SEN). 
Supplementary Table 2. Label-free proteomics quantification data and protein drug 
target identification results based on Regulation and Specificity for Experiment 2. 
Cell lines RKO and A375 treated with DOXO, 5-FU, CAMP and PCTL, as well as 
DMSO (control), or left in unchanged media for senescence/starvation (SEN). 
Supplementary Table 3. Drug target identification results based on drug target 
exceptional behavior for Experiment 1. Cell lines HCT116, A375, H1299 treated with 
5-FU, TDX, MTX, PCTL and DOXO, as well as DMSO (control), or left in 
unchanged media for senescence/starvation (SEN). 
Supplementary Table 4. Lists of top 100 most abundant proteins (set A) and top 100 
most drug-specific proteins (set S).  
Supplementary Figure 1. Protein-protein interaction networks for significant drug 
target protein candidates (rank-product p0.05) for 5-FU, TDX, MTX, PCTL and 
DOXO. 
Supplementary Figure 2. Correlations of specific proteins profiles (TYMS and 
TUBB2A) with all other protein profiles in all treatments (x-axis) and excluding 
treatments with specific drugs (5-FU and PCTL) (y-axis). 
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Supplementary Figure 3. OPLS-DA loading and score plots for discriminative 
model for 5 drugs (PCTL, DOXO, 5-FU, MTX and TDX) based on label-free 
quantitative data of 100 most drug-specific proteins: (a) scores and (b) loadings for 
components 1-4; (c) scores and (d) loadings for components 2-4; (e) scores and (f) 
loadings for components 3-4. 
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ONLINE METHODS 
Cell culture and drug treatments. HCT116 and RKO (colon carcinoma), H1299 
(lung cancer), and A375 (melanoma) cell lines were kindly provided by colleagues 
from Karolinska Institutet. The cells were cultured at 37 °C with 5% CO2 in high-
glucose Dulbecco’s Modified Eagle’s Medium (DMEM, Thermo Fisher Scientific) 
supplemented with 10% fetal bovine serum (Gibco) and 1% penicillin/streptomycin 
(Gibco). The cells were treated for 24-96 h with six different drugs: 5-fluorouracil 
(5FU), raltitraxed or tomudex (TDX), metotrexate (MTX) (all - Sigma), as well as 
doxorubicin (DOXO), paclitaxel (PCTL), and camptothecin (CAMP) (all - Eurasia 
Drugs, China).  Each type of cell was treated with a concentration causing death of 
15-50% of cells after 48 h of treatment. In Experiment 1, the following was used: 
CELL 
LINE 
5FU TDX DOXO PCTX MTX CONTROLS 
 
HCT 
116 
50 µM 100 nM 5 µM 100 nM 5 µM 0h, 48h, SEN 
A375 10 µM 50 nM 100 nM 50 nM 100 nM 0h, 48h, SEN 
H1299 50 µM 10 µM 15 µM 100 nM 5 µM 0h, 48h, SEN 
 
In Experiment 2, the concentrations were 10 µM for 5-FU, 20 µM for TDX, 0.5 µM 
for PCTL, 30 nM for DOXO, and 15 µM for CAMP. 
All drugs were dissolved in 0.01% dimethyl sulfoxide (DMSO). As a negative 
control, cells were treated with 0.01% DMSO. The medium supplemented with the 
drug was replaced each 24 h by fresh medium, except for starved/senescent cells that 
were left in the same medium for 10 days. 
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Protein extraction and digestion. The collected cells were suspended in lysis buffer (1 
mln cells in 100 µL buffer). The buffer was prepared by dissolving 1 mg ProteaseMax 
(Promega) in 900 µL ammonium bicarbonate (50 mM) and 100 µL acetonitrile 
(ACN). ProteaseMax is a surfactant which not only solubilizes the proteins but 
enhances subsequent tryptic digestion of proteins as well. The samples were vortexed 
for 5 min and then heated in shaking thermomixer (Eppendorf) at 50 oC for 30 min at 
1400 rpm, followed by sonication for 30 min. The total protein concentration was 
measured using the BCA protein assay kit (Pierce) in accordance with the 
manufacturer’s protocol. The extracted proteins were reduced with 5.5 mM 
dithiothreitol (DTT), alkylated with 15 mM indole-3-acetic acid (IAA), and digested 
with 1.2 ȝg modified sequencing grade trypsin (Promega) dissolved in 50 mM 
ammonium bicarbonate. After 14 h of tryptic digestion, the reaction was stopped with 
acetic acid to a final concentration of 5% and then heated to 56 oC for 30 min at 500 
rpm, followed by centrifugation for 7 min at 14,000 rpm at room temperature. The 
samples were pre-cleaned in a C18 column Zip-tip (Millipore), and the flow-through 
was dried in a SpeedVac centrifugal evaporator. The dried peptides were dissolved in 
water containing 1% formic acid (Fluka) for LC-MS/MS analysis. The above 
described digestion protocol was performed using the Mass Prep Station Robotic 
Protein Handling System (Waters, Manchester, UK).  
LC-MS/MS experiment. For each sample, 5 µg of peptides were analyzed using 
Orbitrap Q Exactive (Experiments 1, 3/label-free), Orbitrap Velos (Experiment 2) or 
Orbitrap Fusion (Experiment 3/TMT-10) mass spectrometers coupled to a nEasy 
HPLC (all - Thermo Fisher Scientific). Chromatographic separation of peptides was 
achieved using a 50 cm Easy nanoflow column (Thermo; Experiments 1 and 3) or a 
75 µm ID fused silica column packed in-house (Experiment 2) to the length of 8 cm 
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with a slurry of reverse-phase, fully end-capped Reprosil-Pur C18-AQ 3 ȝm resin in 
methanol. The peptides were loaded onto the column at a flow rate of 1000 nL/min, 
and then eluted at a 300 nL/min flow rate for 180-210 min at a linear or biphasic 
gradient from 4% to 35% ACN in 0.1% formic acid. Electrospray ionization of the 
peptides was at 1.5 kV. The MS and MS/MS data was acquired in the Orbitrap mass 
analyzer in a data-dependent acquisition mode. The survey MS spectrum was 
acquired at the resolution of 60,000 in the range of m/z 200 í 2000. MS/MS data 
were obtained with a higher-energy collisional dissociation (HCD) for ions with 
charge z2 at a resolution of 7,500 (Orbitrap Velos) or 15,000 (Q Exactive and 
Fusion).  
Data processing. The raw files were converted to Mascot Generic Format (mgf) using 
in-house written Raw2mgf program. All mgf files were merged to create a common 
mgf file using in-house written Cluster program, which merged individual MS/MS 
spectra sharing more than 12 out of 20 most abundant peaks. The clustered mgf files 
were searched by the MS/MS search engine Mascot (version 2.3.0, Matrix Science, 
UK) to identify peptides and proteins. The mass tolerance was 10 ppm for precursor 
ions and 20 mDa for fragment ions, using carbamidomethyl (C) as a fixed 
modification, oxidation (M) as a variable modification, and up to two missed tryptic 
cleavages. The IPI human database (version 3.68; 91,521 human protein sequences) 
was searched, with reversed protein sequences concatenated as a decoy for 
determining the false discovery rate (FDR). 
Quantitative information was extracted using in-house developed label-free 
software Quanti v.2.5.3.1.15 Only reliably identified (FDR<0.01), unmodified 
peptides with unique sequences were considered and only proteins discovered with at 
least two such peptides were quantified. For each protein, one database identifier (ID) 
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was selected, covering all the peptide sequences identified for this specific protein. If 
two proteins belonging to different protein groups had a partial sequence overlap, then 
all the peptides belonging to this overlap were ignored. The results were reported as a 
set of relative protein abundances A scaled such that the geometric mean of the 
abundance of each protein over all samples was 1.0. 
Scoring system. For combining the data from replicate analysis, “medians of ratios” 
are used instead of “ratios of medians”, as has previously been suggested.24 If relative 
protein abundance of i-th quantified protein in c-th cell line under j-th treatment is 
denoted as ࡭࢏ǡ࢐ࢉ , then regulation Reg is calculated as:  
ࡾࢋࢍ௜ǡ௝௖ ൌ ܯ݁݀݅ܽ݊ ൬ฬ݈݋݃
஺೔ǡೕ೎
஺೔ǡబ
೎ ฬ൰ǡ   (1) 
and specificity Spec is defined as: 
ࡿ࢖ࢋࢉ௜ǡ௝௖ ൌ ܯ݁݀݅ܽ݊௞ஷ௝ ൬ฬ݈݋݃
஺೔ǡೕ೎
஺೔ǡೖ
೎ ฬ൰ǡ  (2) 
where j=0 corresponds to untreated cells for Reg calculation, and jk for Spec 
calculations.  
For each cell line and treatment, the proteins were sorted by Reg and Spec, 
making sure that the direction of Reg and Spec in top proteins were the same 
(otherwise the proteins were forced to the bottom of the list). Then the Reg and Spec 
ranks were summed for all cell lines, and the proteins were sorted in ascending order 
of the summed rank. Top proteins represented the most likely drug target candidates. 
Exceptional behavior measure. For each I-th protein and each J-th drug treatment, 
two vectors were calculated: 
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࡯࢏
ࡵǡכ ൌ ܥ݋ݎݎሺࡾࢋࢍ௜ǡ௝௖ ǡ ࡾࢋࢍூǡ௝஼ ሻ, 
࡯࢏
ࡵǡࡶ ൌ ܥ݋ݎݎሺࡾࢋࢍ௜ǡ௝ஷ௃௖ ǡ ࡾࢋࢍூǡ௝ஷ௃஼ ሻ, 
where ࡯࢏
ࡵǡכ are the Pearson’s correlation coefficients of expression profiles over all 
treatments of i-th and I-th proteins, while ࡯࢏
ࡵǡࡶ are correlation coefficients of the 
expression profiles of i-th and I-th proteins excluding treatment J. Then, the linear 
model ࡯࢏
ࡵǡכ̱࡯࢏
ࡵǡࡶ was created and the coefficient of determination of the model was 
used to calculate the measure of exceptional behavior EI,J of I-th protein under J-th 
treatment: 
ܧூǡ௃ ൌ
ͳ
തܴଶூǡ௃
 
p-value calculation. In estimation of the p-value of a protein with a certain rank, we 
used the rank product method, which has previously been found to be robust and 
tolerant to missing values in detection differentially regulated genes in replicated 
experiments.25 The method has also been successfully applied to proteomics datasets 
for detection of significantly regulated proteins.26 In adaptation of the method by 
Schwämmle et al., we treated Reg and Spec ranks as independent variables, and their 
values for different cell lines as well as at different incubation times were considered 
as independent replicate measurements. The rank product was considered to have a 
gamma distribution under null hypothesis, from which we calculated the p-values for 
the set of ranks of every protein. Adjusted p-values were calculated using standard 
Bonferroni correction, using the total number of proteins as a multiplication factor. 
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